18 August 2026

$5M THREE-YEAR SPECIALISED MEDICAL NUTRITION PROCUREMENT AGREEMENT

Highlights

- **Xenitra's Hong Kong Fukang subsidiary signs a three-year Framework Purchase Agreement with JOY CHARM LIMITED.**
- **The agreement establishes a target aggregate procurement value of A$5 million over three years for Food for Special Medical Purposes (FSMP) products.**
- **The agreement expands Xenitra's healthcare offering into specialized medical nutrition and further builds the commercial pipeline of the recently acquired Fukang business.**
- **Commercial terms provide for a 20% payment following execution of each Purchase Order and receipt of invoice, with the remaining 80% payable following receipt of prescribed shipment documentation.**
- **The agreement follows the recently announced A$12 million Kangsheng pharmaceutical procurement agreement and further commercialises Xenitra's regulated Hong Kong healthcare platform.**
- **Following the acquisition and post merger integration in June, Fukang has achieved strong sales in the July month of over $450k AUD, complementing these contracted procurement agreements.**

---

12 August 2026 Hong Kong, China. Xenitra Limited (ASX:XEN) (Xenitra or the Company) is pleased to advise shareholders that its recently acquired healthcare subsidiary, Hong Kong Fukang Trade Limited ("Fukang"), has entered into a three-year Framework Purchase Agreement with JOY CHARM LIMITED ("Joy Charm") for the supply of Food for Special Medical Purposes ("FSMP") products.

Under the agreement, Joy Charm has agreed to a target aggregate procurement amount of A$5 million during the three-year term from 12 August 2026 to 12 August 2029. Specific products, quantities, pricing and delivery schedules will be agreed through individual Purchase Orders, with FSMP purchases under those orders contributing toward the aggregate procurement target.

The agreement represents a further expansion of the commercial opportunity being developed through Fukang following its acquisition by Xenitra earlier this year. It broadens the platform beyond conventional OTC medicines into specialised medical nutrition, while leveraging the same sourcing, regulatory, logistics and commercial infrastructure. The agreement follows Xenitra's recently announced A$12 million three-year pharmaceutical procurement agreement with Kangsheng and further strengthens the Company's healthcare sales pipeline alongside its Nutritionals and OPAL real-world-asset (RWA) tokenised sales growth pillars.

Non-Executive Chairman, Dr Anthony Noble, said: "Following the acquisition of Fukang, integration and a strong first month sales the A$12 million Kangsheng agreement announced recently and this new A$5 million procurement framework represents further positive steps in building the commercial pipeline through Fukang and demonstrate the breadth of opportunity that acquisition has created for Xenitra. Our ability to operate in the pharmaceutical market also remains an, as yet, untapped revenue stream."

"Importantly, this agreement expands the opportunity beyond conventional OTC medicines and into Food for Special Medical Purposes and specialised nutrition. These are categories which are a natural fit for

Xenitra with our strong capabilities in Nutritionals and OTC Medicine where product quality, international sourcing capability and an understanding of regulated healthcare channels can create meaningful value for both our suppliers and our customers."

"We are beginning to see Fukang develop not simply as an individual business, with an extremely strong first month of sales in July and now in broader healthcare market segments, that align with out strategic focus. Together with our established nutritionals business and the rapid development of the OPAL tokenised sales platform, Xenitra has begun FY27 with all three growth pillars in commercial execution and multiple opportunities to generate higher-quality revenue across our Asian sales ecosystem."

Strategic Importance of the Agreement

- **Further builds the Fukang commercial pipeline**

  The Joy Charm agreement follows the recently announced Kangsheng pharmaceutical procurement agreement and represents a further independent commercial relationship being developed through Fukang. The A$5 million target provides an additional potential source of product sales over the next three years, subject to execution of individual Purchase Orders.

- **Expands Xenitra into specialised medical nutrition (FSMP)**

  The agreement specifically targets Food for Special Medical Purposes (FSMP), expanding the product categories being sourced through Fukang beyond traditional OTC pharmaceutical products and providing Xenitra with an opportunity to participate in an adjacent healthcare and specialised nutrition category.

- **Scalable platform with defined working-capital terms**

  The agreement demonstrates the potential for Fukang's sourcing, logistics and commercial infrastructure to support multiple products and counterparties. Under each Purchase Order, 20% is payable within seven days after execution and receipt of invoice, with the remaining 80% payable within seven days following receipt of the required commercial and shipping documentation, subject to the agreed delivery method, ensuring cash to cash cycle for the business is in line with the broader OTC medicine division.

Food for Special Medical Purposes (FSMP) Market in China

China is a large and rapidly growing market for Food for Special Medical Purposes (FSMP). SAMR data indicates the market grew from approximately RMB7 billion (A$1.5 billion) in 2020 to RMB23 billion (A$4.8 billion) in 2024, representing annualised growth of more than 25%. Imported products remain important, with the value of national FSMP imports increasing by approximately 50% between 2021 and 2023. From 2024, China reduced import tariffs to zero for FSMP products for people aged over three years, extending existing zero-tariff treatment for infant FSMP products. These market and regulatory trends provide a significant opportunity for Xenitra through Fukang.

Over the counter medicines (OTC) Market in China

China represents a large and established market for over-the-counter (OTC) medicines, supported by growing consumer demand for self-medication and convenient access to healthcare products. The Chinese OTC market was estimated at approximately RMB400 billion in 2023, representing annual growth of approximately 9.1%.

OTC medicines also represent a substantial component of China's pharmacy channel, accounting for approximately 43% of retail pharmacy medicine sales in 2024. China's expanding online pharmacy channel provides an additional growth platform, supported by an established NMPA regulatory framework for online medicine sales. These dynamics provide a significant addressable market for Xenitra's expanding OTC medicines business.

Key Terms of the Agreement

Key term	Summary
Parties	Seller: Hong Kong Fukang Trade Limited. Buyer: JOY CHARM LIMITED.
Agreement purpose	Three-year framework for the purchase and supply of FSMP products, with individual commercial details set through Purchase Orders.
Term	Three years, from 12 August 2026 to 12 August 2029.
Procurement target	Target aggregate purchases of A$5 million of FSMP products during the three-year term. The amount is a target and not a guaranteed minimum purchase obligation.
Products	Food for Special Medical Purposes (FSMP). Product names, specifications, quantities and unit prices are determined through individual Purchase Orders.
Purchase Orders	Each Purchase Order will determine product, specification, quantity, unit price, delivery arrangements and other commercial particulars.
Payment terms	20% of each Purchase Order within seven days after execution and receipt of invoice; remaining 80% within seven days following receipt of the required commercial and shipping documentation.
Governing law / disputes	PRC law. Disputes are to be submitted to the China International Economic and Trade Arbitration Commission (CIETAC), Beijing.

-Ends-

This announcement has been approved for release by the Board of Xenitra Limited.

Investor Relations Contact

Harry Spillane | Investor Relations
harry@blackwateradvisors.com.au
+61 447 757 550

About Xenitra Limited

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over the counter (OTC) medicines and personal care products distributed through a channel-optimised sales ecosystem incorporating blockchain-enabled tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and ecommerce platforms in China. Xenitra is one of the first Australian companies to commercially deploy Real World Asset ("RWA") tokenisation integrated directly into mainstream FMCG sales channels in China. The Company's established ecommerce, livestream commerce and distributor infrastructure across China and Australia provides a scalable platform to onboard additional international and domestic brands into the OPAL ecosystem.

Forward Looking Statements

This announcement may contain forward-looking statements, including statements regarding plans, strategies and objectives of management; anticipated revenue, products, and stores; operating costs; Chinese tourism; Governmental policies and preferences (both Australian and Chinese). Forward-looking statements can be identified using terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue', 'annualised' or similar words. These statements discuss future expectations concerning the results of operations or financial condition or provide other forward-looking statements. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements. Except as required by applicable regulations or by law, the Group does not undertake any obligation to publicly update or review any forward-looking statements, whether because of new information or future events. Past performance cannot be relied on as a guide to future performance